Purple Biotech (PPBT) has released an update.
Purple Biotech Ltd., a clinical-stage company focusing on novel oncology therapies, has announced the exercise of warrants resulting in $2 million gross proceeds. These funds, accrued through the sale of American Depositary Shares at a reduced price, will support the development of their therapeutic candidates and general corporate needs. The company also introduced new warrants exercisable at $0.40 per ADS to further bolster their financial resources.
For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.
